Nutra Pharma Corp. (NPHC.OB), a biotechnology company focused on developing drugs for HIV and Multiple Sclerosis, announced that the company has expanded their licensing agreement with NanoLogix, Inc. ( NNLX.PK). Consequently, this agreement will now include the exchange of intellectual property for the testing of NonTuberculous Mycobacterium treatments.
NonTuberculous Mycobacterium, also known as atypical Tuberculosis, is a bacterium that is found in water, including hot tubs and showers, some domestic and wild animals, and soil. One of the most common forms of NTM infections found in humans is Mycobacterium avium complex a leading cause of respiratory disease and a leading cause of death in HIV/AIDS patients.
Rik J. Deitsch, Chairman and CEO of Nutra Pharma, stated, “NTM infections are becoming a major concern for hospitals and medical clinics around the world. Combining our newly licensed intellectual property with our current test kit technology will allow our subsidiary, Designer Diagnostics, to attempt to successfully launch a cost-effective solution to help identify the environmental sources of NTM infections,” he added.
Bret Barnhizer, President and CEO of NanoLogix, added, “Expanding this licensing agreement to include environmental testing is a natural progression of our relationship with Nutra Pharma and our belief in its ability to successfully bring these kits to market. In addition to helping detect NTM in patients, Nutra Pharma will now be able to test for NTM in the environment to help prevent others from becoming infected,” he concluded.
Let us hear your thoughts below:
